EVs and exosomes
Exosomes are a subtype of EV with a specific cellular origin. We use the broader term EV unless that origin has been demonstrated.
A research framework for biological cargo.
Cellular communication is the foundation. EVs, RNA cargo, edible formulation concepts and computational analysis define connected research directions, with experimental evidence needed at each step.
The biological starting point
Extracellular vesicles, or EVs, are membrane-bound particles released by cells. They can carry RNA, proteins, lipids and other molecules.
Established scienceCargo and context
RNA is one part of the cargo. Its composition and the receiving biological system shape the questions an experiment needs to address.
Coding and non-coding RNA
EV-associated cargo can include miRNA, lncRNA, circRNA and protein-coding mRNA. Their presence, abundance and function depend on the source and require sample-specific characterisation.
Established scienceRead more
miRNA
Small non-coding RNAs that can regulate gene expression.
lncRNA
Long non-coding transcripts studied for context-dependent regulatory roles.
circRNA
Circular RNA molecules, including non-coding regulatory species.
mRNA
Protein-coding RNA whose integrity and translation require specific testing.
Biomimetic design
We aim to learn from biological membranes and carrier systems when framing new formulation ideas.
Research directionDefine the system
Specify the source material, carrier composition and intended cargo before evaluating a formulation.
Preserve the distinction
A manufactured carrier inspired by an EV must be characterised on its own terms.
Edible nanoencapsulation
For food applications, our concept considers edible, food-grade materials around biological cargo or its carrier. Protection, release and compatibility remain questions to test.
ConceptRead more
Protection
Compare whether a formulation preserves cargo and vesicle integrity during storage and relevant exposure conditions.
Release
Measure when cargo becomes available and whether its biological activity is retained.
Oral delivery questions
Investigate digestive conditions, mucus and transport barriers before drawing conclusions about uptake or bioavailability.
Material, use and regulatory pathway
Safety and regulatory suitability depend on the substance, formulation, intended use and jurisdiction, including when ingredients are edible or food-grade.
Read more
U.S. food uses and GRAS
GRAS concerns a particular substance under specific conditions of intended use. It is not blanket approval of nanoencapsulation, an EV platform or every resulting product.
Changes in material or process
Nanoscale properties and manufacturing changes can require a fresh safety and regulatory assessment; a conventional ingredient assessment may not transfer.
Therapeutic applications
Therapeutic concepts require a separate product-specific pathway addressing quality, safety and efficacy under the relevant jurisdiction. Food-use status does not authorise a therapeutic use.
Connect the experiment with the analysis
A proposed imaging and multi-omics module would connect wet-lab measurements with in silico hypotheses, then return those hypotheses to experimental testing.
Proposed moduleA related inventor record
Senem Şimşek is a named co-inventor on an international application describing WJ-MSC cell-line work and an AI/ML manufacturing platform. Its record is presented separately from Rnevox development evidence.
From concept to evidence
The public platform outline presents research directions and a proposed evaluation pathway. Integration, performance and application readiness require separate evidence.
Research direction
Define the biological question, source material and intended use.
Concept
Specify a candidate carrier and formulation approach.
Proposed evaluation
Agree measurements, controls and decision criteria before testing.
Evidence-led development
Advance only as reproducibility, function and safety data support the intended use.
Selected sources
Regulatory context
Generally Recognized as Safe (GRAS)FDA. The U.S. framework concerns substances under their intended conditions of food use.
Regulatory context
Assessing significant manufacturing changes in food ingredientsFDA, 2014. Includes nanotechnology and the safety and regulatory consequences of material changes.
Regulatory context
Drug Products, Including Biological Products, that Contain NanomaterialsFDA, 2022. Separate guidance for human drug and biological products; not an approval of a Rnevox concept.